The problem with GLP-1 as a drug candidate had always been its half-life: less than two minutes in the bloodstream before the enzyme DPP-4 degrades it
the order is routed to a retail pharmacy for an FDA-approved brand product or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide
Current evidence does not show that IGF-1 LR3 causes cancer in healthy individuals, but patients with active malignancy or significant risk factors should avoid therapy
Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, et al
The same study revealed that 70% of employers who do not currently cover GLP-1s for obesity would consider adding it if the prices were lower
Further study of the effect of GLP-1 on thyroid follicular cells and longitudinal observation of the association of long-term GLP-1R activation with PTC is needed to clarify the meaning of GLP-1R expression in PTC and the long-term effects of incretin-based therapy on the thyroid
